ArticleMicrobial biotechnology2025
Novel Insights Into the Struggle Against Biofilm: The PsyOmp38 Protein From the Antarctic Marine Bacterium Psychrobacter sp. TAE2020.
Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- New Proteins from Cold: Antibiofilm Activity of Cold-Azurin and PsyOmp38 Against Enterococcus faecalis and Klebsiella pneumoniae.Probiotics and antimicrobial proteins · 2026Article
- Novel Insights Into the Struggle Against Biofilm: The PsyOmp38 Protein From the Antarctic Marine Bacterium Psychrobacter sp. TAE2020.Microbial biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiofilm molecules can enhance the effectiveness of antibiotics and prevent biofilm formation. Antarctic marine bacteria have been found to secrete antibiofilm molecules, likely as part of a strategy for competitive survival. The protein-polysaccharide complex CATASAN, produced by the Antarctic bacterium Psychrobacter sp. TAE2020, has been shown to interfere with all stages of Staphylococcus epidermidis biofilm development. This study investigates the contribution of PsyOmp38, the protein component of CATASAN, to the complex's antibiofilm activity. The protein was heterologously expressed in Escherichia coli, purified, and characterised, revealing its ability to inhibit Staphylococcus epidermidis adhesion to surfaces, interfere with biofilm formation, and disrupt mature biofilms. Following biocompatibility assessment, PsyOmp38 was tested in combination with vancomycin as a potential treatment for established infections, revealing a reduction in the minimum biofilm eradication concentration (MBEC) of vancomycin. The potential of PsyOmp38 for material functionalisation was also explored. The protein was deposited onto silicone-based surfaces, and the coated materials were tested in a continuous-flow system that simulated real-life conditions. Additionally, the three-dimensional structure of PsyOmp38 was predicted and compared with homologous proteins. The structural analysis not only revealed the unique features of PsyOmp38 but also provided important insights into the molecular mechanisms underlying its antibiofilm activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.